Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03379051 |
| Title | Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | TG Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Chicago | Illinois | 60611 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Rochester | New York | 14642 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Cleveland | Ohio | 44195 | United States | Details |